Answers are grounded in this paper and cite their sources.
Systematic review demonstrates increased cardiovascular disease risks in individuals with MAFLD, highlighting severity impact.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is increasingly recognized as a risk factor for cardiovascular disease (CVD) but the association remains unclear. This systematic review and meta-analysis aimed to quantify these associations. Methodology: We searched multiple databases for articles reporting CVD outcomes in MAFLD and conducted meta-analysis. Results: A total of 49 studies encompassing 1,553,770 individuals with MAFLD were included. MAFLD without advanced fibrosis was significantly associated with increased risks of fatal (HR 1.46, 95% CI 1.23-1.73; P <0.01), nonfatal (HR 1.54, CI 1.29-1.84; P <0.01), and combined CVD events (HR 1.60; CI 1.30-1.97; P <0.01). MAFLD with advanced fibrosis was significantly associated with combined CVD events (HR 1.79, CI 1.09-2.92; P <0.01) but not with fatal CVD events (HR 1.23, CI 1.00-1.52; P =0.06) or nonfatal CVD events (HR 1.08, CI 0.82-1.42; P =0.582). Conclusion: MAFLD, even without advanced fibrosis, is an independent risk factor for CVD. The risk is amplified with advanced fibrosis, particularly for combined CVD events.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: